On Friday, Hyderabad-based Bharat Biotech released details of the third phase of testing the vaccine. Consequently, Kovixin was found to be 77.8 percent effective against Kovid-19 with symptoms.
Explaining the experiment’s findings, Bharat Biotech said that covaxin is 93.4 percent effective in people with severe symptoms.
Additionally, the vaccine was found to be up to 63.6 percent effective against the delta variant B1.617.2. The second highest incidence of the disease in the country was in the case of variant B.1.617.2. Expected side effects are less than 0.5 percent on trial.
Also read: India ranks second with record vaccinations; The center says that the second wave in the country is not over; Special guide
The experiment was carried out from November 16, 2020 to January 7, 2021. Bharat Biotech said the test was conducted on 25,800 people between the ages of 18 and 98. The third phase of the experiment was carried out at the vaccination centers of some 25 selected hospitals across the country.